Alps Group Inc filings document the company's foreign private issuer current-report disclosures following its completed SPAC business combination and public-company transition. Form 6-K reports furnish material-event updates, press releases, governance changes, board appointments, committee service, executive leadership appointments, employment agreement terms, capital-structure matters, and security-structure disclosures.
The filing record also covers company-specific biotechnology disclosures, including peer-reviewed case reports involving autologous Natural Killer cell infusions produced with an in-house culture protocol and CELESOME(+) exosome-related development activities. These documents frame Alps Group's formal disclosures around clinical-program communications, corporate governance, material agreements, and operating and financial reporting categories.
Alps Group Inc has appointed Mr. Hee H. Lee to its Board of Directors, effective April 17, 2026, expanding the Board from five to six members. He is considered independent under Nasdaq rules and is expected to join both the Audit Committee and the Compensation Committee.
Mr. Lee is a New York-licensed Certified Public Accountant with more than three decades of public accounting and advisory experience, including as a Partner at Ernst & Young LLP and long-standing advisory work with the International Swaps and Derivatives Association. The company operates an integrated biotechnology and healthcare platform focused on predictive, preventive, and precision medicine.
Alps Group Inc officer Poh Chit Laa has filed an initial statement of beneficial ownership. The filing shows direct ownership of 2,000 Ordinary Shares as of March 18, 2026. This Form 3 does not report any recent purchase, sale, or option exercise, only the existing share position.
Alps Group Inc director Chua Boon Ping filed an initial ownership report showing a direct holding of 150,000 Ordinary Shares. This Form 3 does not record a new purchase or sale but establishes the director’s existing equity stake and confirms direct ownership of these shares.
Alps Group Inc director Chew Yoke Ling has filed an initial ownership report showing a substantial equity stake in the company. The Form 3 discloses direct ownership of 6,882,720 Ordinary Shares as of the reported date. This filing records existing holdings and does not reflect any new buy or sell transaction.
Alps Group Inc executive Cheing Lye-Ping, the Chief Financial Officer, has filed an initial statement of beneficial ownership on Form 3. The data provided shows no reported purchases, sales, gifts, tax withholdings, restructurings, or derivative exercises, indicating no insider trading activity is disclosed in this excerpt.
Alps Group Inc director Mohamed Suleiman bin has filed an initial ownership report on Form 3. This filing establishes his status as a director of the company and indicates that there are currently no reportable transactions or derivative positions listed in the submission.
Alps Group Inc executive Manickam Ravichandran, the Chief Scientific Officer, has filed an initial insider ownership report. The filing shows direct ownership of 20,000 Ordinary Shares, establishing his reported equity stake in the company but not reflecting any recent buy or sell transaction.
Alps Group Inc executive Low Wei Sim, the Chief Operating Officer, has filed an initial ownership report showing a direct holding of 821,083 Ordinary Shares. This filing is a Form 3, which records the officer’s existing stake and does not reflect a new buy or sell transaction.
Alps Group Inc director and Chief Executive Officer Tham Seng Kong filed an initial ownership report showing a substantial direct stake in the company. The filing reports beneficial ownership of 77,144,380 Ordinary Shares, confirming his status as a major, more than ten percent, shareholder.
Alps Group Inc filed a Form 6-K highlighting a peer-reviewed case series of its autologous Natural Killer (NK) cell therapy using an in-house culture protocol. The study in SAGE Open Medical Case Reports followed nine patients treated at ALPS Medical Centre between 2023 and 2024.
Patients were monitored for blood counts, liver function, hypersensitivity, inflammatory markers and tumor markers to evaluate safety and potential toxic or dose-dependent adverse reactions. The case series provided evidence of clinical tolerability of autologous NK cells produced with the company’s proprietary protocol and complied with Malaysian Good Clinical Practice and the Declaration of Helsinki.
The company also emphasized a patent-pending, antibody-free culture method that aims to enable cost-effective, large-scale production of highly pure NK cells using basic media and autologous plasma. These preliminary data, together with preclinical GLP findings, are intended to support future clinical investigations in a broader patient population.